Abstract 500
Background
There are 30000 to 40000 head and neck cancers cases in United States each year. Radiotherapy is one of the best treatment options in these patients. Unfortunately, Xerostomia is one of most common side effects. This study aimed to evaluate effect of autologous platelet rich plasma (PRP) and PRP along with peripheral blood cells (PC) application in treatment of radiation induced xerostomia for the first time in the world.
Methods
21 patients with head and neck cancers who suffered from post radiation xerostomia were selected regard to inclusion criteria. Patients were divided into PRP or PRP + PC group randomly. They were followed up for 6 months. Data was analyzed by SPSS version 20 and parametric and nonparametric tests
Results
21 patients with the age between 20 and 61 years were entered the pilot study. 47.6% were female and other was male. Mean left parotid uptake to back ground (first month after injection) in PRP and RPR + PC group was 0.31 ± 1.6 and 1.3± 0.62 and this difference was significant (P = 0.33). This index in right submandibul (sixth month after injection) was -0.31 ± 0.43 and 1.3 ± 1.2 (P = 0/033). All quality of life parameters show improvement in first and sixth month after treatment (P
Conclusions
All quality of life parameters show improvement after treatment and these findings were qualified by objective results of Scintigraphy scan. Absorption parameters in Scintigraphy show significant improvement in all salivary glands. Secretion parameters show significant improvement in both parotid glands not sub mandibular glands. These may be due to small sample size or short follow up period. Result of scan showed that PRP + PC are more effective than RPR
Clinical trial identification
Legal entity responsible for the study
N/A
Funding
Mashhad University of Medical Sciences
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
ZUMA-3: A phase 1/2 multi-center study evaluation the safety and efficacy of KTE-C19 anti-CD19 CAR T cells in adult patients with relapsed/refractory B precursor acute lymphoblastic leukemia (R/R ALL)
Presenter: Bijal Shah
Session: Poster display
Resources:
Abstract
ZUMA-2: A phase 2 multi-center study evaluating the efficacy of KTE-C19 (Anti-CD19 CAR T cells) in patients with relapsed/refractory Mantle cell lymphoma (R/R MCL)
Presenter: Michael Wang
Session: Poster Display
Resources:
Abstract
ZUMA-1: A phase 2 multi-center study evaluating anti-CD19 chimeric antigen receptor (CAR) T cells in patients with refractory aggressive non-Hodgkin lymphoma (NHL)
Presenter: Sattva Neelapu
Session: Poster Display
Resources:
Abstract
Younger age as a prognostic indicator in breast cancer: Correlation between clinical-pathologic factors and miRNAs and long-term follow-up
Presenter: Maria Teresa Martinez
Session: Poster display
Resources:
Abstract
Window study of the PARP inhibitor rucaparib in patients with primary triple negative or BRCA1/2 related breast cancer (RIO)
Presenter: Christy Toms
Session: Poster display
Resources:
Abstract
Whole exome sequencing (WES) and RNA sequencing (RNA-seq) in routine clinical practice for colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) patients (pts)
Presenter: Géraldine Perkins
Session: Poster display
Resources:
Abstract
What is the optimal annual interpretive volume for a radiologist reading screening mammograms?
Presenter: Asli Uluturk
Session: Poster display
Resources:
Abstract
What decides breast conservation versus mastectomy in the background of diverse sociocultural environment, an Indian study
Presenter: Poonamalle Padmanabhan Bapsy
Session: Poster display
Resources:
Abstract
Waiting time to diagnosis and treatment of the head and neck cancer in four institutions in Portugal
Presenter: Ana Castro
Session: Poster display
Resources:
Abstract
Wait times for diagnosis and treatment of lung cancer: a single centre experience
Presenter: Catherine Labbe
Session: Poster Display
Resources:
Abstract